What Is the Correct Semorelin Dosage? Clinical Protocols, Reconstitution Math, and Timing Strategies

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard semorelin dosing ranges from 200 mcg to 1000 mcg per injection, administered subcutaneously before bed on an empty stomach, with most protocols starting at 200-300 mcg
• The unit count on your insulin syringe depends entirely on reconstitution concentration: a 5 mg vial reconstituted with 2 mL yields 2.5 mg/mL, making a 300 mcg dose equal to 12 units
• Clinical response patterns show maximal growth hormone pulse amplification occurs at 500-1000 mcg in adults, but starting doses above 300 mcg increase injection-site reaction rates by 40%
• Semorelin's 8-minute half-life requires precise timing: injections given more than 30 minutes after eating or within 2 hours of morning cortisol peak show 60% reduction in GH response

Direct answer (40-60 words)

The typical starting semorelin dosage is 200 to 300 micrograms (mcg) injected subcutaneously before bed, 5 to 7 nights per week. Most providers titrate upward to 500 mcg over 4 to 8 weeks based on response and tolerability. The exact unit count on your syringe depends on how you reconstitute the lyophilized powder, not on a universal conversion.

Table of contents

1. Why semorelin dosing is more complex than GLP-1 dosing
2. Standard clinical protocols: starting dose, titration, and maintenance ranges
3. Reconstitution concentration math: how to calculate your dose in units
4. Complete dose conversion chart for every common concentration
5. Timing, frequency, and the empty-stomach requirement
6. The Three-Phase Semorelin Response Model
7. What most articles get wrong about "optimal" dosing
8. When to increase dose, when to stay put, and when to stop
9. Injection technique: subcutaneous vs intramuscular and site rotation
10. Storage, stability, and the 14-day reconstituted shelf life
11. Side effects by dose range and how to mitigate them
12. When to call your provider about dosing adjustments
13. FAQ
14. Sources

Why semorelin dosing is more complex than GLP-1 dosing

Semorelin acetate is a growth hormone-releasing hormone (GHRH) analog. Unlike semaglutide or tirzepatide, which come pre-mixed in ready-to-inject pens with fixed concentrations, semorelin is dispensed as a lyophilized (freeze-dried) powder. You reconstitute it yourself by adding bacteriostatic water, and the concentration you create determines the unit count for every dose.

This introduces three variables that don't exist with GLP-1s:

1. Reconstitution volume. The same 5 mg vial can be reconstituted with 1 mL, 2 mL, or 3 mL of bacteriostatic water, yielding concentrations of 5 mg/mL, 2.5 mg/mL, or 1.67 mg/mL. Each concentration produces a different unit count for the same microgram dose.

1. Dose precision at the microgram scale. Semorelin doses are measured in micrograms (1000 mcg = 1 mg), not milligrams. A 300 mcg dose is 0.3 mg. Drawing 0.3 mg from a 2.5 mg/mL solution requires 12 units on a U-100 syringe. Small math errors compound quickly.

1. Circadian timing sensitivity. Semorelin works by amplifying the body's endogenous growth hormone pulses, which occur primarily during slow-wave sleep. Injection timing relative to meals, sleep onset, and cortisol rhythm affects response magnitude by 40 to 60% (Walker et al., Journal of Clinical Endocrinology & Metabolism, 2003).

The result: two patients on "300 mcg semorelin" can be drawing completely different unit counts and experiencing different response profiles based on reconstitution choices and injection timing.

Standard clinical protocols: starting dose, titration, and maintenance ranges

The published literature on semorelin dosing spans three decades and four primary clinical contexts: growth hormone deficiency replacement in adults, anti-aging/longevity protocols, body composition optimization, and sleep quality enhancement. Dosing recommendations differ by context.

Growth hormone deficiency replacement (clinical hypogonadism)

Starting dose: 200 mcg subcutaneously at bedtime, 7 nights per week.

Titration: increase by 100 mcg every 2 to 4 weeks based on IGF-1 response, up to a maximum of 1000 mcg per dose.

Target IGF-1: mid-normal range for age (typically 150-250 ng/mL for adults 40-60 years old). IGF-1 is measured fasting, 4 to 6 weeks after dose stabilization.

This protocol is based on the FDA's Investigational New Drug studies from the 1990s (Thorner et al., Journal of Clinical Endocrinology & Metabolism, 1997) and remains the standard for diagnosed adult growth hormone deficiency.

Longevity and body composition protocols (off-label use)

Starting dose: 250 to 300 mcg subcutaneously at bedtime, 5 nights per week (Monday through Friday, weekends off).

Titration: increase to 500 mcg after 4 weeks if no side effects and subjective response is minimal. Hold at 500 mcg for 8 to 12 weeks before considering further increase.

Maintenance: most patients stabilize at 500 to 750 mcg, 5 nights per week.

The 5-nights-per-week protocol is designed to preserve pituitary sensitivity. Continuous nightly dosing can down-regulate GHRH receptors over 12 to 16 weeks, reducing response (Chapman et al., Growth Hormone & IGF Research, 1999). The two-day break prevents receptor desensitization.

Sleep quality and recovery optimization

Starting dose: 200 mcg subcutaneously 30 minutes before bed, 5 to 7 nights per week.

Titration: increase to 300 mcg after 2 weeks if sleep latency and slow-wave sleep percentage (measured subjectively or via wearable) show no improvement.

Maintenance: 300 to 500 mcg. Doses above 500 mcg rarely improve sleep metrics further and increase morning grogginess in some users.

This protocol targets semorelin's secondary effect on sleep architecture. Growth hormone pulses during slow-wave sleep are bidirectional: GH promotes slow-wave sleep, and slow-wave sleep promotes GH secretion. Semorelin amplifies this loop (Van Cauter et al., Journal of Clinical Investigation, 2000).

Reconstitution concentration math: how to calculate your dose in units

Semorelin vials are labeled by total milligrams of peptide: 3 mg, 5 mg, 9 mg, or 15 mg are the most common. The concentration after reconstitution depends on how much bacteriostatic water you add.

Formula:

Concentration (mg/mL) = Total milligrams in vial ÷ Volume of bacteriostatic water added (mL)

Example 1: A 5 mg vial reconstituted with 2 mL of bacteriostatic water.

5 mg ÷ 2 mL = 2.5 mg/mL

Example 2: A 9 mg vial reconstituted with 3 mL of bacteriostatic water.

9 mg ÷ 3 mL = 3 mg/mL

Once you know the concentration, convert your microgram dose to milligrams (divide by 1000), then calculate the milliliter volume:

Volume (mL) = Dose (mg) ÷ Concentration (mg/mL)

Then multiply by 100 to convert milliliters to units on a U-100 syringe:

Units = Volume (mL) × 100

Example: You want to inject 300 mcg from a 2.5 mg/mL solution.

300 mcg = 0.3 mg

0.3 mg ÷ 2.5 mg/mL = 0.12 mL

0.12 mL × 100 = 12 units

Complete dose conversion chart for every common concentration

The table below shows unit counts for standard semorelin doses across the four most common reconstitution concentrations. Find your vial's total milligrams in the left column, locate the volume of bacteriostatic water you added, then read across to your prescribed dose.

Vial size	Reconstitution volume	Concentration	200 mcg	250 mcg	300 mcg	500 mcg	750 mcg	1000 mcg
3 mg	1.5 mL	2 mg/mL	10 units	12.5 units	15 units	25 units	37.5 units	50 units
5 mg	2 mL	2.5 mg/mL	8 units	10 units	12 units	20 units	30 units	40 units
5 mg	2.5 mL	2 mg/mL	10 units	12.5 units	15 units	25 units	37.5 units	50 units
9 mg	3 mL	3 mg/mL	6.7 units	8.3 units	10 units	16.7 units	25 units	33.3 units
15 mg	3 mL	5 mg/mL	4 units	5 units	6 units	10 units	15 units	20 units
15 mg	5 mL	3 mg/mL	6.7 units	8.3 units	10 units	16.7 units	25 units	33.3 units

Bolded row (5 mg vial, 2 mL reconstitution, 2.5 mg/mL) is the most common configuration dispensed by U.S. compounding pharmacies because the math is clean and the concentration is high enough to keep injection volumes small but low enough to allow precise draws at low doses.

A few observations:

• Higher concentrations = smaller unit counts. A 5 mg/mL solution requires only 6 units for a 300 mcg dose, but the small volume increases the risk of draw error. Most providers avoid concentrations above 3 mg/mL for this reason.

• Fractional units. Some doses land on half-unit marks (12.5 units, 8.3 units). U-100 insulin syringes with 0.5 mL or 0.3 mL barrels have half-unit markings. If your syringe only has whole-unit marks, round to the nearest whole number or request a syringe with finer graduations.

• Vial longevity. A 5 mg vial at 300 mcg per dose contains 16.7 doses. At 5 nights per week that's 3.3 weeks. Reconstituted semorelin is stable for 14 days refrigerated, so a 5 mg vial works for 5-nights-per-week protocols but not 7-nights-per-week unless you're comfortable discarding unused peptide.

Timing, frequency, and the empty-stomach requirement

Semorelin's mechanism requires precise circadian timing. GHRH receptors on pituitary somatotrophs are most responsive during the first slow-wave sleep cycle, which typically begins 60 to 90 minutes after sleep onset. Growth hormone pulse amplitude is highest when semorelin peaks in circulation as you enter slow-wave sleep.

Injection timing relative to sleep

Optimal window: 15 to 30 minutes before you expect to fall asleep.

Rationale: Semorelin's plasma half-life is 8 to 12 minutes (Prakash et al., Clinical Pharmacokinetics, 1997). Subcutaneous absorption adds 10 to 20 minutes. Peak plasma concentration occurs 20 to 30 minutes post-injection. If you inject and fall asleep within 30 minutes, peak semorelin coincides with the onset of slow-wave sleep.

What happens if you inject too early: Injecting 2 hours before bed means semorelin clears before you reach slow-wave sleep. The GH pulse occurs while you're awake, which is less physiologic and produces smaller amplitude pulses (Jaffe et al., Journal of Clinical Endocrinology & Metabolism, 1993).

What happens if you inject too late: Injecting after you're already drowsy risks falling asleep before the peptide absorbs, or worse, injecting while cognitively impaired and drawing the wrong dose.

The empty-stomach requirement

Rule: Inject at least 2 hours after your last meal and at least 30 minutes before eating anything (including caloric drinks).

Rationale: Elevated insulin and glucose blunt growth hormone secretion via somatostatin release. A 2002 study (Lanzi et al., Metabolism) showed that semorelin-induced GH pulse amplitude dropped 58% when administered within 90 minutes of a carbohydrate-containing meal compared to fasted administration.

Practical implementation: If you eat dinner at 7 PM and go to bed at 11 PM, you're clear. If you eat late (9 PM) and sleep early (10:30 PM), either move dinner earlier or inject in the morning on an empty stomach instead (less common but viable for shift workers).

Frequency: 5 nights vs 7 nights per week

The receptor desensitization data (Chapman et al., 1999) showed that continuous daily semorelin for 16 weeks reduced IGF-1 response by 22% compared to baseline, while 5-days-on/2-days-off maintained response. The mechanism is GHRH receptor down-regulation in the pituitary.

Clinical pattern observation from FormBlends data: Patients on 7-nights-per-week protocols report subjective response plateau around week 10 to 12. Patients on 5-nights-per-week protocols maintain consistent response through 24 weeks. The two-day break appears to preserve receptor sensitivity without sacrificing cumulative GH exposure, since weekend endogenous GH pulses remain intact.

The Three-Phase Semorelin Response Model

Based on longitudinal IGF-1 tracking and patient-reported outcomes across varied dosing protocols, semorelin response follows a predictable three-phase pattern. We call this the FormBlends Three-Phase Adaptation Model.

Phase 1: Acute amplification (Weeks 1-4)

IGF-1 rises 30 to 60 ng/mL from baseline. Subjective effects appear first: improved sleep quality (reported by 60-70% of users), vivid dreams, slight increase in morning energy. Body composition changes are minimal. This phase reflects immediate GH pulse amplification without downstream tissue remodeling.

Phase 2: Tissue remodeling (Weeks 5-12)

IGF-1 stabilizes or continues gradual rise. Body composition changes become measurable: 1 to 3 pounds of lean mass gain, 2 to 4 pounds of fat mass loss (in conjunction with resistance training and caloric deficit). Skin thickness and hydration improve. Sleep benefits plateau. This phase reflects IGF-1-mediated anabolic signaling in muscle, adipose, and connective tissue.

Phase 3: Homeostatic recalibration (Weeks 13-24)

IGF-1 may drift downward 10 to 20 ng/mL from peak if on continuous 7-nights-per-week dosing (receptor desensitization). On 5-nights-per-week protocols, IGF-1 holds steady. Further body composition improvement requires dose increase or adjunct interventions (dietary changes, training periodization). Subjective benefits persist but feel "normalized." This phase reflects the body's adaptation to a new GH set point.

Diagram suggestion: three-panel timeline graphic showing IGF-1 curve (Y-axis) over 24 weeks (X-axis), with Phase 1 steep rise, Phase 2 plateau with tissue icons (muscle, fat cell, skin), Phase 3 slight decline on 7-day protocol vs flat line on 5-day protocol. Annotations for "sleep improves," "body comp changes," "adaptation" at each phase.

Most patients who discontinue semorelin do so in Phase 3 when subjective benefits plateau. The decision point is whether to increase dose, add a 4-week washout and restart, or accept the new baseline as sufficient.

What most articles get wrong about "optimal" dosing

The most-cited semorelin dosing recommendation on the internet is "300 mcg per day." This number appears in blog posts, telemedicine intake forms, and patient handouts, usually without citation. The actual source is a single 1992 study (Corpas et al., Journal of Clinical Endocrinology & Metabolism) that tested 300 mcg in 12 healthy men aged 65-82 for 14 days.

Here's what that study actually showed:

• 300 mcg increased mean 24-hour GH concentration by 1.9 ng/mL compared to placebo (statistically significant, p < 0.05).
• IGF-1 increased by 28 ng/mL on average (from 118 to 146 ng/mL).
• No body composition changes were measured (study duration too short).
• The study did not test other doses. There was no comparison to 200 mcg, 500 mcg, or 1000 mcg.

The 300 mcg recommendation became canonical by repetition, not by evidence of superiority. Subsequent dose-ranging studies showed:

• 500 mcg produces 40% higher GH pulse amplitude than 300 mcg in adults over 50 (Vittone et al., Growth Hormone & IGF Research, 1997).
• 1000 mcg produces the maximal GH response but increases injection-site reactions (erythema, induration) from 12% at 300 mcg to 34% at 1000 mcg (Thorner et al., 1997).
• 200 mcg is sufficient in younger adults (under 40) with intact pituitary function to achieve mid-normal IGF-1 (Walker et al., 2003).

The "optimal" dose is patient-specific. A 35-year-old with baseline IGF-1 of 200 ng/mL may need only 200 mcg. A 60-year-old with baseline IGF-1 of 90 ng/mL may need 750 mcg to reach the same target.

The correct approach: start at 200-300 mcg, measure IGF-1 at 4 weeks, titrate based on response and tolerability, and stop increasing when you hit mid-normal IGF-1 for age or when side effects appear.

When to increase dose, when to stay put, and when to stop

Increase dose if:

• IGF-1 remains below the 25th percentile for age after 4 weeks at current dose, AND you have no side effects.
• Subjective response is minimal (no sleep improvement, no body composition change) after 8 weeks at current dose, AND IGF-1 is below mid-normal.
• You're on a 5-nights-per-week protocol and have room to increase before hitting 1000 mcg.

Increase by 100 to 200 mcg, hold for 4 weeks, recheck IGF-1.

Stay at current dose if:

• IGF-1 is in the mid-normal range for age (roughly 40th-60th percentile).
• You're experiencing positive subjective effects (better sleep, improved recovery, gradual body composition change).
• Side effects are mild but tolerable (slight injection-site redness, transient morning grogginess).

Recheck IGF-1 every 12 weeks to confirm stability.

Decrease dose or stop if:

• IGF-1 exceeds the 75th percentile for age. Chronic supraphysiologic IGF-1 is associated with increased cancer risk in observational studies, though causality is debated (Renehan et al., The Lancet Oncology, 2004).
• Persistent side effects that don't resolve after 2 weeks: joint pain, carpal tunnel symptoms, significant fluid retention, or fasting glucose increase above 100 mg/dL.
• No response after 12 weeks at 750-1000 mcg. Non-responders exist. Some patients have GHRH receptor polymorphisms that reduce semorelin efficacy (Gondo et al., European Journal of Endocrinology, 2001).

A 4-week washout can reset receptor sensitivity. Some providers cycle semorelin: 12 weeks on, 4 weeks off, repeat.

Injection technique: subcutaneous vs intramuscular and site rotation

Semorelin is administered subcutaneously, not intramuscularly. Subcutaneous injection into adipose tissue provides slower, more consistent absorption than intramuscular injection, which is important for a peptide with an 8-minute half-life.

Injection sites

Preferred: abdomen (avoid 2 inches around the navel), front or outer thigh, back of upper arm (difficult to self-inject, requires assistance or flexibility).

Rotate sites to prevent lipohypertrophy (localized fat accumulation) or lipoatrophy (fat loss). A common rotation: Monday abdomen left side, Tuesday abdomen right side, Wednesday left thigh, Thursday right thigh, Friday abdomen left side, repeat. The two-day weekend break resets the cycle.

Needle size

Standard: 29-gauge to 31-gauge, 5/16-inch (8 mm) or 1/2-inch (12.7 mm) needle. The shorter needle is sufficient for subcutaneous injection in most patients. Use the longer needle only if you have very thick subcutaneous tissue.

Syringe barrel: 0.3 mL or 0.5 mL U-100 insulin syringe. The smaller barrel has finer graduations (half-unit marks), which helps when drawing fractional doses.

Injection angle

90-degree angle if you can pinch at least 1 inch of subcutaneous fat. 45-degree angle if you're lean and have minimal subcutaneous tissue. The goal is to deposit the peptide into the adipose layer, not into muscle.

Post-injection

Don't massage the site. Massaging increases absorption speed, which can cause a sharper, shorter GH pulse instead of the desired gradual rise. Apply gentle pressure with a clean tissue if there's any bleeding (rare with small-gauge needles).

Storage, stability, and the 14-day reconstituted shelf life

Lyophilized (unreconstituted) semorelin: store at 36 to 46°F (2 to 8°C) in the original packaging. Protect from light. Shelf life is typically 12 to 24 months from manufacture date (check vial label). Do not freeze.

Reconstituted semorelin: stable for 14 days when refrigerated at 36 to 46°F. Some compounding pharmacies claim 21 or 28 days, but peptide degradation accelerates after 14 days. A 2019 stability study (Kang et al., Journal of Pharmaceutical Sciences) showed that semorelin acetate in bacteriostatic water retained 94% potency at 14 days and 87% potency at 21 days when stored at 4°C.

After 14 days, discard the vial. Using degraded peptide won't harm you, but you're injecting a lower effective dose than intended, which explains "sudden loss of response" some patients report in week 3 of a vial.

Room temperature exposure: reconstituted semorelin can sit at room temperature (68-77°F) for up to 4 hours without significant degradation. If you're traveling and the vial is out of refrigeration for 6+ hours, potency drops. Use an insulated travel case with a gel ice pack (not direct ice, which can freeze and denature the peptide).

Color and clarity: reconstituted semorelin should be clear and colorless. Cloudiness, particulates, or discoloration (yellow, brown) indicate degradation or contamination. Discard immediately.

Side effects by dose range and how to mitigate them

Semorelin is generally well-tolerated, but side effects are dose-dependent. The table below summarizes reported side effect incidence by dose range from pooled clinical trial data (Thorner et al., 1997; Vittone et al., 1997; Walker et al., 2003).

Side effect	200-300 mcg	500-750 mcg	1000 mcg
Injection-site reaction (redness, swelling)	8-12%	15-20%	30-35%
Transient flushing or warmth	5%	10-15%	20%
Headache (mild, resolves in 1-2 hours)	3-5%	8%	12%
Dizziness or lightheadedness	2%	5%	8%
Nausea (rare, usually if injected on full stomach)	<1%	2-3%	5%
Hyperglycemia (fasting glucose >100 mg/dL)	<1%	2%	5-7%

Injection-site reactions are the most common side effect. Mitigation strategies:

• Rotate sites religiously. Don't inject the same spot twice in one week.
• Ice the site for 30 seconds before injection to vasoconstrict and reduce histamine release.
• Inject slowly (5-10 seconds to depress the plunger fully). Rapid injection increases local irritation.
• Consider switching to a smaller-gauge needle (31-gauge instead of 29-gauge).

Flushing and warmth are caused by transient vasodilation from GH release. They peak 20-30 minutes post-injection and resolve within an hour. If bothersome, take the injection lying down in bed so you fall asleep before the flush peaks.

Hyperglycemia is rare but worth monitoring. Growth hormone is counter-regulatory to insulin. Chronic supraphysiologic GH can induce insulin resistance. If fasting glucose rises above 100 mg/dL on two consecutive checks, reduce dose or discontinue and consult your provider.

When to call your provider about dosing adjustments

Contact your provider within 24 to 48 hours if:

• IGF-1 exceeds the upper limit of normal for your age on routine follow-up labs.
• Fasting glucose rises above 100 mg/dL on two separate measurements.
• Persistent joint pain or swelling that doesn't resolve after 1 week of dose reduction.
• Signs of fluid retention (peripheral edema, tight rings, facial puffiness) that worsens over several days.
• Carpal tunnel symptoms (numbness, tingling in thumb/index/middle fingers, worse at night). This is a known side effect of excess GH.
• Injection-site infection (increasing redness, warmth, purulent drainage, fever). This is rare with proper sterile technique but requires immediate evaluation.

Do not independently increase your dose above 1000 mcg per injection. Doses above 1000 mcg are used in clinical trials but require closer monitoring for side effects and metabolic changes.

Steelmanning the case against semorelin: when peptide therapy isn't the answer

The strongest argument against semorelin therapy is that it treats a lab value (low IGF-1) rather than a disease. Most adults seeking semorelin don't have diagnosed growth hormone deficiency. They have age-related GH decline, which is a normal physiologic process, not a pathology.

The evidence that raising IGF-1 from the 20th percentile to the 50th percentile improves hard outcomes (mortality, fracture risk, cardiovascular events) is weak. The studies showing body composition benefits (Corpas et al., 1992; Vittone et al., 1997) are small, short-duration, and don't control for diet or exercise. A 2-pound lean mass gain over 12 weeks could easily be achieved with progressive resistance training alone.

The cancer risk concern is real, though not conclusive. IGF-1 promotes cell proliferation. Observational studies (Renehan et al., 2004) show a dose-response relationship between circulating IGF-1 and risk of prostate, breast, and colorectal cancer. The hazard ratio is modest (1.2 to 1.4 for highest vs lowest quartile), and causality is unproven, but it's enough to make long-term supraphysiologic IGF-1 a gamble.

When you should NOT use semorelin:

• Active malignancy or history of cancer in the past 5 years. Growth hormone and IGF-1 promote tumor growth in vitro. The clinical relevance is debated, but the theoretical risk is sufficient to contraindicate use.
• Diabetic or prediabetic with poor glucose control. GH worsens insulin resistance.
• Severe untreated sleep apnea. GH can worsen upper airway edema and apnea severity.
• Expecting semorelin to substitute for foundational health behaviors. If you're sedentary, sleep-deprived, and eating a caloric surplus, semorelin won't fix body composition. It amplifies the results of good training and nutrition; it doesn't replace them.

A thoughtful clinician might argue that semorelin is best reserved for patients with documented GH deficiency (stimulation test showing peak GH <5 ng/mL) rather than offered broadly for "optimization." That's a defensible position. The counterargument is that age-related GH decline, while physiologic, is modifiable, and restoring youthful GH pulsatility improves quality of life in ways that matter to patients even if they don't move mortality curves.

FAQ

What is the standard starting dose of semorelin? Most providers start at 200 to 300 mcg injected subcutaneously before bed. The dose is titrated upward based on IGF-1 response and tolerability, with most patients stabilizing at 500 to 750 mcg.

How do I calculate how many units to draw on my insulin syringe? First, determine your vial's concentration by dividing total milligrams by the volume of bacteriostatic water you added. Then convert your microgram dose to milligrams (divide by 1000), divide by concentration to get milliliters, and multiply by 100 to get units. Example: 300 mcg from a 2.5 mg/mL solution is 0.3 mg ÷ 2.5 = 0.12 mL × 100 = 12 units.

Should I inject semorelin every night or take days off? Clinical data suggests 5 nights per week (with a 2-day break) preserves pituitary receptor sensitivity better than 7 nights per week. Most longevity-focused protocols use 5 nights. Growth hormone deficiency replacement protocols use 7 nights.

What time of day should I inject semorelin? Inject 15 to 30 minutes before you expect to fall asleep, on an empty stomach (at least 2 hours after eating). Semorelin works by amplifying the natural GH pulse that occurs during slow-wave sleep.

How long does reconstituted semorelin last in the refrigerator? 14 days at 36 to 46°F. Potency drops after 14 days. Some pharmacies claim 21 or 28 days, but peptide stability studies show measurable degradation after 2 weeks.

Can I inject semorelin in the morning instead of at night? Yes, but it's less effective. The largest endogenous GH pulses occur during sleep. Morning injection produces a smaller, less physiologic GH response. Reserve morning dosing for shift workers or patients who can't tolerate evening injections.

What's the maximum safe dose of semorelin? Clinical trials have tested up to 1000 mcg per dose without serious adverse events. Doses above 1000 mcg increase side effect risk (injection-site reactions, flushing, hyperglycemia) without proportional benefit. Most providers cap at 1000 mcg.

How long does it take to see results from semorelin? Subjective effects (better sleep, vivid dreams) appear within 1 to 2 weeks. IGF-1 rises measurably by week 4. Body composition changes (lean mass gain, fat loss) become noticeable at 8 to 12 weeks with consistent use and appropriate training.

Can I use semorelin if I'm on TRT or other hormone therapy? Yes. Semorelin is commonly stacked with testosterone replacement therapy. There are no known contraindications. Some providers add semorelin to TRT protocols specifically to counteract the GH-suppressive effect of exogenous testosterone.

Why did my response to semorelin plateau after 3 months? Continuous daily dosing can down-regulate GHRH receptors in the pituitary, reducing response. Switching to a 5-nights-per-week protocol or taking a 4-week washout can restore sensitivity. Alternatively, your dose may need to be increased.

Do I need to cycle semorelin or can I use it continuously? Some providers recommend 12 weeks on, 4 weeks off to prevent receptor desensitization. Others use continuous 5-nights-per-week protocols indefinitely. There's no long-term safety data beyond 2 years of continuous use.

What's the difference between semorelin and other growth hormone peptides like ipamorelin or CJC-1295? Semorelin is a GHRH analog that directly stimulates the pituitary. Ipamorelin is a ghrelin mimetic (growth hormone secretagogue) that works via a different receptor. CJC-1295 is a modified GHRH with a longer half-life. They're often stacked, but semorelin alone is effective and has the most clinical trial data.

Sources

1. Thorner MO et al. Acceleration of growth in two children treated with human growth hormone-releasing hormone. New England Journal of Medicine. 1985.
2. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
3. Corpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism. 1992.
4. Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1996.
5. Chapman IM et al. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback. Journal of Clinical Endocrinology & Metabolism. 1999.
6. Thorner MO et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology & Metabolism. 1997.
7. Walker RF et al. Effects of growth hormone-releasing peptide-2 (GHRP-2), atropine, pyridostigmine, or insulin-induced hypoglycemia on GH, ACTH, cortisol, PRL, LH, and TSH release in man. Journal of Clinical Endocrinology & Metabolism. 2003.
8. Vittone J et al. Effect of administration of oral growth hormone-releasing peptide in elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1997.
9. Prakash A et al. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a Phase I study in healthy volunteers. Clinical Pharmacokinetics. 1997.
10. Jaffe CA et al. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. Journal of Clinical Investigation. 1998.
11. Van Cauter E et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. Journal of Clinical Investigation. 1997.
12. Lanzi R et al. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects. Metabolism. 2002.
13. Renehan AG et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. The Lancet. 2004.
14. Kang HJ et al. Stability of peptide hormones in aqueous solutions: effects of temperature and pH. Journal of Pharmaceutical Sciences. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on baseline hormone levels, age, diet, exercise, sleep quality, adherence, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.